Arthur A. Levin has been selected as a new member of the board of directors at Avidity Biosciences, a biopharmaceutical firm dedicated to bringing innovative RNA therapies to market. He will switch from his position as chief scientific officer to that of distinguished scientist and head of strategy.

One of the company’s co-founders, Troy Wilson, expressed that Avidity is “grateful to Art for his scientific leadership, invaluable contributions in developing AOCs, life-long commitment to patients and dedication to our mission of revolutionizing the delivery of RNA therapeutics."

“Arthur A. Levin has been selected as a new member of the board of directors at Avidity Biosciences“

Avidity’s Chief Executive Officer, Sarah Boyce, explained how "Art's vision” meant “we were able to demonstrate the first-ever successful targeted delivery of RNA into muscle, a revolutionary advancement for Avidity and the RNA field.”

Dr. Michael Flanagan, who has been part of Avidity’s team since January 2021, has also experienced a change in position from chief technical officer to chief scientific and technical officer.

The biopharma firm expressed their "congratulations to Mike on his promotion to chief scientific and technical officer. He has worked alongside Art for the last two years and is an instrumental leader within research and across Avidity.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.